Purna Pharmaceuticals

Purna Pharmaceuticals is a well-established Belgian CDMO with over 30 years of experience, serving a global clientele from small start-ups to top-10 pharmaceutical multinationals. Its core business is providing end-to-end contract services, including development, scale-up, and commercial manufacturing under GMP/FDA standards, with specific expertise in complex formulations like corticosteroids and cytotoxic drugs. Beyond services, Purna actively builds a product pipeline for out-licensing and facilitates partnerships for innovative technologies, positioning itself as a flexible and integrated partner in the pharma value chain.

Integrated CDMO platform offering end-to-end services from API to commercial product. Specializes in analytical and formulation development for complex products (semi-solids, liquids, powders), including potent and cytotoxic compounds. Capabilities include GMP manufacturing, scale-up, IMP clinical supply, and full regulatory support with QbD/DoE approach.

Purna competes in the global CDMO market against large, multi-site players (e.g., Lonza, Catalent) and smaller, specialized firms. Its differentiation lies in its deep expertise in semi-solids and complex drugs, its integrated one-site model reducing transfer risk, and its additional services as a licensing facilitator and NGO supplier.